GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » Cash Ratio

Avalon Globocare (Avalon Globocare) Cash Ratio : 0.04 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Avalon Globocare's Cash Ratio for the quarter that ended in Dec. 2023 was 0.04.

Avalon Globocare has a Cash Ratio of 0.04. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Avalon Globocare's Cash Ratio or its related term are showing as below:

ALBT' s Cash Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.42   Max: 18.04
Current: 0.04

During the past 10 years, Avalon Globocare's highest Cash Ratio was 18.04. The lowest was 0.04. And the median was 0.42.

ALBT's Cash Ratio is ranked worse than
86.99% of 1775 companies
in the Real Estate industry
Industry Median: 0.32 vs ALBT: 0.04

Avalon Globocare Cash Ratio Historical Data

The historical data trend for Avalon Globocare's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalon Globocare Cash Ratio Chart

Avalon Globocare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.28 0.18 0.56 0.04

Avalon Globocare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.17 0.11 0.05 0.04

Competitive Comparison of Avalon Globocare's Cash Ratio

For the Real Estate Services subindustry, Avalon Globocare's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalon Globocare's Cash Ratio Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Avalon Globocare's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Avalon Globocare's Cash Ratio falls into.



Avalon Globocare Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Avalon Globocare's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.285/6.763
=0.04

Avalon Globocare's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.285/6.763
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avalon Globocare  (NAS:ALBT) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Avalon Globocare Cash Ratio Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalon Globocare (Avalon Globocare) Business Description

Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Executives
Lourdes Felix director 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin director 901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu director, 10 percent owner C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders director 431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu director 14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy director 611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola officer: Chief Financial Officer 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin director, officer: CEO and President C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li director C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li director, officer: Chief Operating Officer C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel director 33 ALPINE DRIVE, MORGANVILLE NJ 07751

Avalon Globocare (Avalon Globocare) Headlines

From GuruFocus

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

By GuruFocusNews GuruFocusNews 06-24-2022